Intelligent Bio Solutions Inc.

NasdaqCM INBS

Intelligent Bio Solutions Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -326.06%

Intelligent Bio Solutions Inc. EBIT Margin is -326.06% for the Trailing 12 Months (TTM) ending September 30, 2024, a 42.41% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Intelligent Bio Solutions Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -566.16%, a 78.27% change year over year.
  • Intelligent Bio Solutions Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -2,605.21%.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
NasdaqCM: INBS

Intelligent Bio Solutions Inc.

CEO Mr. Harry Simeonidis
IPO Date Dec. 23, 2020
Location United States
Headquarters 142 West 57th Street
Employees 50
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

StockViz Staff

January 15, 2025

Any question? Send us an email